GTHX Stock Overview
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
G1 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.11 |
| 52 Week High | US$5.00 |
| 52 Week Low | US$1.08 |
| Beta | 1.69 |
| 1 Month Change | 11.08% |
| 3 Month Change | 20.18% |
| 1 Year Change | 52.22% |
| 3 Year Change | -81.54% |
| 5 Year Change | -77.90% |
| Change since IPO | -72.60% |
Recent News & Updates
Recent updates
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22G1 Therapeutics granted regulatory nod for cancer therapy in China
Jul 13G1 Therapeutics: Needs To Expand Labels And Commercialize Better
Apr 27Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential
Feb 08G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07G1 Therapeutics: Market May Be Terribly Underestimating This Company
Nov 20G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 03G1 Therapeutics: Poised To Deliver A Blockbuster
Aug 28G1 Therapeutics: Pullback Presents Opportunity
Aug 16News Flash: Analysts Just Made A Captivating Upgrade To Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasts
Aug 08Shareholder Returns
| GTHX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.7% | -4.7% | -3.7% |
| 1Y | 52.2% | -2.7% | 20.2% |
Return vs Industry: GTHX exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: GTHX exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| GTHX volatility | |
|---|---|
| GTHX Average Weekly Movement | 22.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GTHX's share price has been volatile over the past 3 months.
Volatility Over Time: GTHX's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 100 | Jack Bailey | www.g1therapeutics.com |
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.
G1 Therapeutics, Inc. Fundamentals Summary
| GTHX fundamental statistics | |
|---|---|
| Market cap | US$214.54m |
| Earnings (TTM) | -US$47.97m |
| Revenue (TTM) | US$82.51m |
2.6x
P/S Ratio-4.5x
P/E RatioIs GTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTHX income statement (TTM) | |
|---|---|
| Revenue | US$82.51m |
| Cost of Revenue | US$7.20m |
| Gross Profit | US$75.32m |
| Other Expenses | US$123.28m |
| Earnings | -US$47.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 91.28% |
| Net Profit Margin | -58.13% |
| Debt/Equity Ratio | 145.7% |
How did GTHX perform over the long term?
See historical performance and comparison